A journey through infectious risk associated with ruxolitinib

Emanuela Sant’Antonio, Massimiliano Bonifacio, Massimo Breccia, Elisa Rumi

Research output: Contribution to journalReview article

Abstract

Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval led to a significant change in the current treatment algorithm. Despite its efficacy and beyond its well described haematological toxicity, a peculiar immunosuppressive effect emerged as our clinical experience grew, both within and outside of a clinical trial setting. Definite and negative interactions with multiple pathways of the immune system of patients have been reported so far, involving both adaptive and innate immune responses. These pathophysiological mechanisms may contribute to the increased risk of reactivation of silent infections (e.g., tuberculosis, hepatitis B virus and varicella zoster virus) that have been associated with the drug. Even though such infectious events may be fatal or may lead to significant impairment of organ function, compromising the eligibility of patients for an allotransplant procedure, there are no dedicated guidelines that may help us in assessing and managing the risk of developing serious infections. On this basis, our aim for the present work was to review the current knowledge on the pathophysiological mechanisms through which ruxolitinib may exert its immunosuppressive effect, and to illustrate our personal approach to the management of three peculiar clinical scenarios, for which a risk-based algorithm is suggested.

Original languageEnglish
JournalBritish Journal of Haematology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Immunosuppressive Agents
Polycythemia Vera
Primary Myelofibrosis
Human Herpesvirus 3
Adaptive Immunity
Infection
Innate Immunity
Hepatitis B virus
Immune System
Tuberculosis
Clinical Trials
Guidelines
Therapeutics
Pharmaceutical Preparations
INCB018424

Keywords

  • infection
  • management
  • myelofibrosis
  • polycythaema vera
  • ruxolitinib

ASJC Scopus subject areas

  • Hematology

Cite this

A journey through infectious risk associated with ruxolitinib. / Sant’Antonio, Emanuela; Bonifacio, Massimiliano; Breccia, Massimo; Rumi, Elisa.

In: British Journal of Haematology, 01.01.2019.

Research output: Contribution to journalReview article

Sant’Antonio, Emanuela ; Bonifacio, Massimiliano ; Breccia, Massimo ; Rumi, Elisa. / A journey through infectious risk associated with ruxolitinib. In: British Journal of Haematology. 2019.
@article{98a5401e9f364f82bfd2e1d13cd92dd1,
title = "A journey through infectious risk associated with ruxolitinib",
abstract = "Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval led to a significant change in the current treatment algorithm. Despite its efficacy and beyond its well described haematological toxicity, a peculiar immunosuppressive effect emerged as our clinical experience grew, both within and outside of a clinical trial setting. Definite and negative interactions with multiple pathways of the immune system of patients have been reported so far, involving both adaptive and innate immune responses. These pathophysiological mechanisms may contribute to the increased risk of reactivation of silent infections (e.g., tuberculosis, hepatitis B virus and varicella zoster virus) that have been associated with the drug. Even though such infectious events may be fatal or may lead to significant impairment of organ function, compromising the eligibility of patients for an allotransplant procedure, there are no dedicated guidelines that may help us in assessing and managing the risk of developing serious infections. On this basis, our aim for the present work was to review the current knowledge on the pathophysiological mechanisms through which ruxolitinib may exert its immunosuppressive effect, and to illustrate our personal approach to the management of three peculiar clinical scenarios, for which a risk-based algorithm is suggested.",
keywords = "infection, management, myelofibrosis, polycythaema vera, ruxolitinib",
author = "Emanuela Sant’Antonio and Massimiliano Bonifacio and Massimo Breccia and Elisa Rumi",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/bjh.16174",
language = "English",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",

}

TY - JOUR

T1 - A journey through infectious risk associated with ruxolitinib

AU - Sant’Antonio, Emanuela

AU - Bonifacio, Massimiliano

AU - Breccia, Massimo

AU - Rumi, Elisa

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval led to a significant change in the current treatment algorithm. Despite its efficacy and beyond its well described haematological toxicity, a peculiar immunosuppressive effect emerged as our clinical experience grew, both within and outside of a clinical trial setting. Definite and negative interactions with multiple pathways of the immune system of patients have been reported so far, involving both adaptive and innate immune responses. These pathophysiological mechanisms may contribute to the increased risk of reactivation of silent infections (e.g., tuberculosis, hepatitis B virus and varicella zoster virus) that have been associated with the drug. Even though such infectious events may be fatal or may lead to significant impairment of organ function, compromising the eligibility of patients for an allotransplant procedure, there are no dedicated guidelines that may help us in assessing and managing the risk of developing serious infections. On this basis, our aim for the present work was to review the current knowledge on the pathophysiological mechanisms through which ruxolitinib may exert its immunosuppressive effect, and to illustrate our personal approach to the management of three peculiar clinical scenarios, for which a risk-based algorithm is suggested.

AB - Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval led to a significant change in the current treatment algorithm. Despite its efficacy and beyond its well described haematological toxicity, a peculiar immunosuppressive effect emerged as our clinical experience grew, both within and outside of a clinical trial setting. Definite and negative interactions with multiple pathways of the immune system of patients have been reported so far, involving both adaptive and innate immune responses. These pathophysiological mechanisms may contribute to the increased risk of reactivation of silent infections (e.g., tuberculosis, hepatitis B virus and varicella zoster virus) that have been associated with the drug. Even though such infectious events may be fatal or may lead to significant impairment of organ function, compromising the eligibility of patients for an allotransplant procedure, there are no dedicated guidelines that may help us in assessing and managing the risk of developing serious infections. On this basis, our aim for the present work was to review the current knowledge on the pathophysiological mechanisms through which ruxolitinib may exert its immunosuppressive effect, and to illustrate our personal approach to the management of three peculiar clinical scenarios, for which a risk-based algorithm is suggested.

KW - infection

KW - management

KW - myelofibrosis

KW - polycythaema vera

KW - ruxolitinib

UR - http://www.scopus.com/inward/record.url?scp=85071376666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071376666&partnerID=8YFLogxK

U2 - 10.1111/bjh.16174

DO - 10.1111/bjh.16174

M3 - Review article

AN - SCOPUS:85071376666

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -